Simone Fishburn

@FishburnSimone

Editor in Chief : Innovation in biopharma, idea to patient; Breaking barriers, one woman at a time. Views are mine, hope to make them yours too.

Bay Area CA
Vrijeme pridruživanja: siječanj 2012.

Tweetovi

Blokirali ste korisnika/cu @FishburnSimone

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @FishburnSimone

  1. proslijedio/la je Tweet
    prije 19 sati

    to begin enrolling patients mid-Feb in 2 trials of to treat acute respiratory disease via 's

    Poništi
  2. proslijedio/la je Tweet
    prije 22 sata

    BioCentury is providing open access to its ongoing coverage and analysis of the outbreak.

    Poništi
  3. 4. velj

    GSK to provide adjuvant to boost effectiveness, stretch supplies of vaccines. In (No paywall)

    Poništi
  4. 4. velj

    Gilead prepares for Chinese trial of antiviral after treating U.S. patient. In (no paywall)

    Poništi
  5. 4. velj

    Clinical trials for coronavirus have begun. First up: approved antivirals and steroids. In (No paywall)

    Poništi
  6. 4. velj

    The Coronavirus outbreak: Letter from the Editor. — coverage on biomedical countermeasures; effect on clinical trials and supply chain; and more. Free to all, no paywall.

    Poništi
  7. proslijedio/la je Tweet
    4. velj

    Gilead preparing a trial in China of remdesivir to treat 2019-nCoV: . Meanwhile, at least 9 trials of #2019-nCoV therapies are underway. All BioCentury coverage of the outbreak is in front of the paywall at .

    Poništi
  8. proslijedio/la je Tweet
    3. velj

    A milestone year for Roche's CNS gambit could kick off its plan for the decade - BioCentury: A milestone year for Roche's CNS gambit could kick off its plan for the decade  BioCentury

    Poništi
  9. 2. velj

    Folks - is continuing to cover the outbreak, which is outside the paywall. This contains the therapeutic & preventive developments, policy actions, and biopharma response.

    Poništi
  10. 1. velj

    Well that’s a wrap on Europe for the UK (😞). But UK biotech still wants to tango. We‘ve got the companies, you’ve got the regulators- let’s dance. with the story, in .

    Poništi
  11. proslijedio/la je Tweet
    31. sij

    A dozen #2019-nCoV vaccine development programs have been announced, five efforts to discover and develop therapeutic antibodies.

    Poništi
  12. 30. sij

    CVS eliminating co-pays for insulin and diabetes meds. A step in the right direction say biopharma leaders who want to uphold the social contract. Via in

    Poništi
  13. 29. sij

    Had the pleasure of doing a Fireside Chat with at , and she is certainly moving the needle on this issue. Having a successful academic entrepreneur speak out is huge. A name to watch in all events.

    Poništi
  14. 28. sij

    One class act is this ! We hand her off to PwC with the warmest of wishes, knowing she will excel there as she does everywhere. She leaves a great legacy , and will extend her leadership, covering now translation to clin dev.

    Poništi
  15. 28. sij

    I’m too old for this , seriously. Unbelievable champion.

    Poništi
  16. proslijedio/la je Tweet
    26. sij

    Biocentury articles are really top notch landscapes with target antigens

    Poništi
  17. 26. sij

    With all eyes on the outbreak, and have an in-depth look at how biotechs are tackling it -- faster and broader than for previous outbreaks. Via .

    Poništi
  18. 25. sij

    Want to know who’s doing what to get CAR Ts to solid tumors? Winnie Pong has sliced and diced the data in . Take-home message: the majority are going after non-validated targets. Less of the lemming factor than in other areas of IO.

    Poništi
  19. 24. sij

    The text you never want to get: “check your car for swastikas.” Husband found this on his. Really ??

    Poništi
  20. proslijedio/la je Tweet

    . Francis Collins gets out his crystal ball and looks ahead to 2020 in this nice interview with Karen Tkach Tuzman of :

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·